711 related articles for article (PubMed ID: 11803184)
1. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Hacke W
Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
[TBL] [Abstract][Full Text] [Related]
2. Evidence with antiplatelet therapy and ADP-receptor antagonists.
Easton JD
Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
[TBL] [Abstract][Full Text] [Related]
3. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
[TBL] [Abstract][Full Text] [Related]
4. Insights from CURE: using clopidogrel on top of standard therapy.
Morais J
Cerebrovasc Dis; 2002; 13 Suppl 1():17-21. PubMed ID: 11803183
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
6. Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Teal PA
Cerebrovasc Dis; 2004; 17 Suppl 3():6-10. PubMed ID: 14730252
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel: a review of its use in the prevention of atherothrombosis.
Jarvis B; Simpson K
Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
[TBL] [Abstract][Full Text] [Related]
9. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ;
Lancet; 2004 Jul 24-30; 364(9431):331-7. PubMed ID: 15276392
[TBL] [Abstract][Full Text] [Related]
10. Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
Bogousslavsky J
Cerebrovasc Dis; 2001; 11 Suppl 2():5-10. PubMed ID: 11316916
[TBL] [Abstract][Full Text] [Related]
11. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
12. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Tran H; Anand SS
JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
15. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Ringleb PA; Bhatt DL; Hirsch AT; Topol EJ; Hacke W;
Stroke; 2004 Feb; 35(2):528-32. PubMed ID: 14739421
[TBL] [Abstract][Full Text] [Related]
16. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P; Sechenova O; Hennekens CH
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy in populations at high risk of atherothrombosis.
Faxon DP; Nesto RW
J Natl Med Assoc; 2006 May; 98(5):711-21. PubMed ID: 16749646
[TBL] [Abstract][Full Text] [Related]
18. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial.
Hankey GJ; Johnston SC; Easton JD; Hacke W; Mas JL; Brennan D; Mak KH; Bhatt DL; Fox KA; Topol EJ;
Int J Stroke; 2011 Feb; 6(1):3-9. PubMed ID: 21205234
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
[TBL] [Abstract][Full Text] [Related]
20. Future perspectives for optimizing oral antiplatelet therapy.
Easton JD
Cerebrovasc Dis; 2001; 11 Suppl 2():23-8. PubMed ID: 11316919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
